Immunomodulatory Therapies for COVID-19 in Solid Organ Transplant Recipients

被引:0
作者
Mario Fernández-Ruiz
José María Aguado
机构
[1] Instituto de Investigación Sanitaria Hospital “12 de Octubre” (imas12),Unit of Infectious Diseases, Hospital Universitario “12 de Octubre”
[2] Centro de Actividades Ambulatorias,Department of Medicine, School of Medicine
[3] Universidad Complutense,undefined
来源
Current Transplantation Reports | 2020年 / 7卷
关键词
COVID-19; Solid organ transplantation; Immunomodulatory therapy; Tocilizumab; Canakinumab; Colchicine;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:379 / 389
页数:10
相关论文
共 495 条
[1]  
Tang Y(2020)Cytokine storm in COVID-19: the current evidence and treatment strategies Front Immunol 11 1708-422
[2]  
Liu J(2020)Pathological findings of COVID-19 associated with acute respiratory distress syndrome Lancet Respir Med 8 420-550
[3]  
Zhang D(2017)New fronts emerge in the influenza cytokine storm Semin Immunopathol 39 541-127
[4]  
Xu Z(2018)Cytokine release syndrome J Immunother Cancer 6 56-1062
[5]  
Ji J(2020)Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19 J Allergy Clin Immunol 146 119-136
[6]  
Wen C(2020)Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Lancet. 395 1054-1948
[7]  
Xu Z(2020)Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19 J Allergy Clin Immunol 146 128-727
[8]  
Shi L(2020)Immunosuppression drug-related and clinical manifestation of coronavirus disease 2019: a therapeutical hypothesis Am J Transplant 20 1947-947
[9]  
Wang Y(2014)IL-6 biology: implications for clinical targeting in rheumatic disease Nat Rev Rheumatol 10 720-328
[10]  
Zhang J(2018)FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome Oncologist. 23 943-10975